SlideShare a Scribd company logo
1 of 22
Download to read offline
Forward Looking Statements
Statements made in this presentation include financial estimates and forward-looking
statements that are not historical facts. Each of these estimates and forward-looking
statements involves risk and uncertainties. These estimates are based on present
circumstances, information currently available, and assumptions about future
revenues, industry growth, and general economic conditions. Estimates are inherently
uncertain as they are based on assumptions concerning future events. No
representations can be made as to the accuracy of such information or the reliability
of such assumptions. Accordingly, actual revenues and expenditures may vary
significantly from the Company’s estimates, and actual results or developments may
differ materially from those expressed or implied by the forward-looking statements.
Factors that could cause actual results to differ from the financial estimates and
forward-looking statements in this presentation include those described in the
Company’s filings with the Securities and Exchange Commission, including the “Risk
Factors” section of the Company’s Annual Report on Form 10-K for the year ended
December 31, 2013, as updated in 2014 quarter periods. Therefore, neither the
Company’s estimates nor the assumptions upon which they are based are to be
interpreted as a guarantee or promise of the Company or management. The
Company has no obligation to modify, amend, update, alter, or change the estimates
contained herein.
Investor Relations
Zynex, Inc.
9990 Park Meadows Drive
Lone Tree, CO 80124
Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynex.com
Apr 2014 2OTCQB: ZYXI
Zynex Overview
•  Medical Device Manufacturer & Compound Pharmacy
o  Non-invasive, conservative pain treatment
o  Neuro-Monitoring
o  Blood volume monitoring
o  Physician and hospital billing
o  International sales
•  Publicly Traded OTCQB: ZYXI
•  In operation since 1996, headquartered in Lone Tree, Colorado
•  >40%+ recurring revenue with more than 250,000 patients treated since inception
•  High GPM of >70%
•  Estimated $5b market potential
Apr 2014 3OTCQB: ZYXI
Business Structure
Zynex, Inc.
Medical Inc.
Electrotherapy
PharmaZy
(Compound
Pharmacy)
Neurodiagnostics
Inc.
EEG (Brain
Diagnostic)
Sleep (lab/home)
(Diagnostic/
Treatment
Monitoring
Solutions
Blood Volume
Monitor (R&D)
Billing and
consulting
Private
Practice Billing
International
Apr 2014 4OTCQB: ZYXI
Business Unit Summary
•  ZYNEX MEDICAL (ZMI)
o  Non-invasive electrotherapy pain management devices “TENS” (97% of historical
revenue)
•  RX required, insurance billed
•  >70% GP, >40% recurring revenue (consumable supplies)
o  Topical/transdermal pain cream (introduced Dec 2013)
•  RX required, insurance billed, complimentary to TENS with same sales force
•  >80% GP and recurring monthly refill prescriptions
•  ZYNEX NEURODIAGNOSTICS (ZND)
o  EEG EMG diagnostics B:B products (2% of historical revenue)
•  ZYNEX MONITORING SOLUTIONS (ZMS)
o  In development, non-invasive blood volume monitor (Zero revenue, in
development)
•  ZYNEX BILLING AND CONSULTING (ZBC)
o  Outsourced billing for physicians and hospitals (1% of historical revenue)
•  ZYNEX INTERNATIONAL (ZINT)
o  International sales for all Zynex products (1% of historical revenue-all divisions)
Apr 2014 5OTCQB: ZYXI
Products – Zynex Medical
•  Complete line of electrotherapy pain
management devices-FDA cleared and CE
marked
•  Augments healing, alleviates swelling through
increased blood circulation, and reduces both
acute/chronic pain through the use of
electrical currents
•  Consumables required
•  Require a prescription
•  Reimbursed by health insurance
•  May be rented or purchased
Apr 2014 6
NexWave
TruWave+
E-Wave
IF8000
IF8100
Iontophoresis
Consumables (battery/electrode)
OTCQB: ZYXI
Products – Zynex Medical
•  Stroke/spinal cord rehabilitation
devices-FDA cleared and CE
marked
•  Augment healing, as well as
assist in recovery for stroke,
Spinal Cord Injuries and
Traumatic Brain Injury, retrains
muscles, increases range of
motion
•  Consumables required
Apr 2014 7
NeuroMove
Consumables (electrodes)
OTCQB: ZYXI
Products – Monitoring Solutions
•  In development – non invasive blood
volume monitor
•  Used in operating and recovery
rooms to detect blood loss and
internal bleeding
•  Clinical trials commenced
•  Patent filed
Apr 2014 8
Blood Volume Monitor
(in development)
OTCQB: ZYXI
Revenue Growth
0
5,000,000
10,000,000
15,000,000
20,000,000
25,000,000
30,000,000
35,000,000
40,000,000
45,000,000
'03 '04 '05 '06 '07 '08 '09 '10 11 12 13
Apr 2014 9OTCQB: ZYXI
Financial Summary
Apr 2014 10OTCQB: ZYXI
Annual Financial Data
(000’s) except per share
2013 2012 2011 2010 2009 2008 2007
Net Revenue $21,684 $39,666 $34,148 $24,085 $18,681 $11,764 $8,048
Gross Profit 13,544 30,896 26,777 18,883 14,888 9,524 7,319
Net Income (loss) (7,301) 1,553 1,564 350 2,382 111 2,131
Cash 323 823 789 602 863 -- --
EPS (0.23) 0.05 0.05 0.01 0.08 0.00 0.07
Cash Flow from
Operations
(382) (879) (362) (665) 3,648 (715) 746
Total Stockholders’
Equity
4,848 12,055 10,140 8,182 7,486 4,774 3,618
Common Shares
Outstanding
31,171 31,148 30,800 30,600 30,500 29,900 26,800
	
  
Balance Sheet
Apr 2014 11OTCQB: ZYXI
Dec-­‐13 Dec-­‐12 Dec-­‐11
Cash 323	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   823	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   789	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
A/R 7,033	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   12,224	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   10,984	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
Inventory 5,002	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   6,160	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   4,557	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
Other	
  Assets 1,346	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   2,155	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   1,718	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
	
  	
  	
  Current	
  Assets 13,704	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   21,362	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   18,048	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
PP&E 2,891	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   3,851	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   3,422	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
Other	
  Assets 626	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   723	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   315	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
	
  	
  	
  Total	
  Assets 17,221$	
  	
  	
  	
  	
  	
  	
  	
  	
   25,936$	
  	
  	
  	
  	
  	
  	
  	
  	
   21,785$	
  	
  	
  	
  	
  	
  	
  	
  	
  
Line	
  of	
  Credit 5,820	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   5,906	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   3,290	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
Other	
  Liabilities 3,864	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   6,187	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   6,460	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
	
  	
  	
  Current	
  Liabilities 9,684	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   12,093	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   9,750	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
Other	
  Liabilities 2,689	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   1,788	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   1,896	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
	
  	
  	
  Total	
  Liabilities 12,373	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   13,881	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   11,646	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
Common	
  Stock 31	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   31	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   31	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
Paid-­‐in-­‐capital 5,586	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   5,453	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   5,095	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
Retained	
  Earnings (735)	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   6,566	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   5,013	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
Noncontrolling	
  interest (34)	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   5	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   -­‐	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
	
  	
  	
  Total	
  Stockholders'	
  Equity 4,848	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   12,055	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   10,139	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
	
  	
  	
  Total	
  Liab.	
  And	
  S.Equity 17,221$	
  	
  	
  	
  	
  	
  	
  	
  	
   25,936$	
  	
  	
  	
  	
  	
  	
  	
  	
   21,785$	
  	
  	
  	
  	
  	
  	
  	
  	
  
Available Market
Apr 2014 12OTCQB: ZYXI
PAST AVAILABLE MARKET ~$4B CURRENT AVAILABLE MARKET ~$5B
ZYNEX MEDICAL ZYNEX MEDICAL
Electrotherapy Devices $550M Electrotherapy Devices $275M
Compound Pain Cream $1.8B
ZYNEX MONITORING SOLUTIONS ZYNEX MONITORING SOLUTIONS
Cardiac Monitoring Devices $3B Cardiac Monitoring Devices $3B
ZYNEX NEURODIAGNOSTICS ZYNEX NEURODIAGNOSTICS
Biofeedback/Rehab $220M Biofeedback/Rehab $220M
Market size based on internal management estimates and various market sources
Business Factors
•  Zynex Medical – TENS
o  TENS business slowed down in 2013
•  Healthcare reform
o  TENS business beginning to grow again early 2014
•  Zynex Medical – Compound Pharmacy
o  Compound pharmacy growth will have impact on second half 2014 financial
results
Apr 2014 13OTCQB: ZYXI
Zynex – Looking Forward
•  Zynex Medical (ZMI)
o  Pain Cream/Compound Pharmacy facts
•  Complements Zynex TENS non-invasive pain management product and
is sold through same TENS channel and customer
•  Highly fragmented with low concentration
•  GM 80%+
•  Zynex is licensed by DEA and 32 states (moving to be licensed in all states
during 2014)
Apr 2014 14OTCQB: ZYXI
Zynex – Looking Forward
•  Zynex Monitoring Solutions:
o  Blood Volume Monitor at commercialization
•  Early warning that patient condition is likely to deteriorate
•  Utilizes multiple physiological
•  Enables a higher level of care than traditional vital sign monitoring
•  Effective in multiple care environments (e.g. operating room, recovery and
trauma)
•  Zynex Billing and Consulting(ZBC)
o  Insurance billing and consulting for physicians and hospitals
o  Looking to assume/acquire additional billing companies
o  Provides recurring service based revenue, while leveraging insurance billing core
competency
Apr 2014 15OTCQB: ZYXI
Future Objectives
•  Listing on AMEX/NASDAQ
•  Develop devices and applications with high GPM
•  Continue to grow recurring revenue
•  Take only calculated risks
•  Generate net earnings and positive free cash flow
•  Long term - utilize a mix of acquisitions and organic based growth to drive
valuation=stock price=private equity with low dilution and/or loan-based financing
Apr 2014 16OTCQB: ZYXI
History
1996
•  Founded by Thomas Sandgaard
1999
•  FDA clearance on first Zynex device
2001
•  Shifted from wholesale to direct sales to physicians and patients
2004
•  Reverse merger into a public shell
2008
•  Received European CE mark on key products
2010
•  Established NeuroDiagnostics (EEG/Sleep) and Monitoring (blood volume) subsidiaries
2011
•  Commenced clinical evaluations for Blood Volume Monitor device
2013
•  Impacted by Health Care Reform – restructured core business, expanded product offers to in-house
compounded pain cream
2014
•  Launched compound pharmacy (DEA + 32 state licenses obtained)
Apr 2014 17OTCQB: ZYXI
Corporate & Ownership Structure
Apr 2014 18
Common Stock: 31,000,000 shares outstanding
OTCBB: ZYXI
Auditors: GHP Horwath
Counsel: Perkins Coie
OTCQB: ZYXI
Management Team Bio
Thomas Sandgaard has been the Chairman of the Board, President and Chief
Executive Officer of Zynex, Inc. since founding the company in 1996. He has
previously held management positions with companies such as ITT, Siemens, GN
Danavox, Dataco and Philips. Most of his work has been in the areas of international
sales and distribution, technology transfers, mergers and marketing management in
the semiconductor, telecommunications, data communications and medical
equipment industries. Mr. Sandgaard has a degree in electronics engineering from
Denmark’s Odense University of Engineering and an MBA from Copenhagen
Business School. Mr. Sandgaard has an in-depth knowledge of the industry and is the
driving force as to the Company strategies.
Anthony Scalese has been Chief Financial Officer of Zynex, Inc. since September
2010. Mr. Scalese has over 15 years of experience in accounting, finance and
operations and has spent the past 13 years of his career in the high-tech and
healthcare industries. His most recent position was Chief Financial Officer for
Qualmark Corporation, in which he also served as President for various subsidiaries
of Qualmark. He previously held positions at Coram Healthcare (now Apria
Healthcare) as well as Foundation Health Systems (now Healthnet). Mr. Scalese is a
Certified Public Accountant licensed in Colorado, received a Masters in Business
Administration from the University of Colorado and a Bachelor of Science in Business
Administration-Accounting from Colorado State University.
Apr 2014 19OTCQB: ZYXI
Summary
Apr 2014 20OTCQB: ZYXI
Contact Information
For more information, please contact:
Investor Relations
Zynex, Inc.
9990 Park Meadows Drive
Lone Tree, CO 80124
Telephone: (303) 703-4906 Facsimile: (303) 347-9153
www.zynex.com
Apr 2014 21OTCQB: ZYXI
Stock Symbol
ZYXI	
  
Apr 2014 22OTCQB: ZYXI

More Related Content

What's hot

Hci 2012 2_q_con_eng_final_
Hci 2012 2_q_con_eng_final_Hci 2012 2_q_con_eng_final_
Hci 2012 2_q_con_eng_final_Hyundai Finance
 
MindTree: Prospect looks upbeat; buy
MindTree: Prospect looks upbeat; buyMindTree: Prospect looks upbeat; buy
MindTree: Prospect looks upbeat; buyIndiaNotes.com
 
Apresentao3 t10 ing
Apresentao3 t10 ingApresentao3 t10 ing
Apresentao3 t10 ingOgx2011
 
Resultados2008
Resultados2008Resultados2008
Resultados2008Ogx2011
 
Expeditors International of Washington, 4th07qer
Expeditors International of Washington, 4th07qerExpeditors International of Washington, 4th07qer
Expeditors International of Washington, 4th07qerfinance39
 
2분기 영문 검토보고서
2분기 영문 검토보고서2분기 영문 검토보고서
2분기 영문 검토보고서Hyundai Finance
 
MindTree: Sharpened focus on growth, but rich valuation, accumulate - Prabhud...
MindTree: Sharpened focus on growth, but rich valuation, accumulate - Prabhud...MindTree: Sharpened focus on growth, but rich valuation, accumulate - Prabhud...
MindTree: Sharpened focus on growth, but rich valuation, accumulate - Prabhud...IndiaNotes.com
 
Credit Corp - turnaround in performance
Credit Corp - turnaround in performance Credit Corp - turnaround in performance
Credit Corp - turnaround in performance George Gabriel
 
Apresentação 3 t11 inglês
Apresentação 3 t11 inglêsApresentação 3 t11 inglês
Apresentação 3 t11 inglêsOgx2011
 
Expeditors International of Washington, 2nd07qer
Expeditors International of Washington, 2nd07qerExpeditors International of Washington, 2nd07qer
Expeditors International of Washington, 2nd07qerfinance39
 
Danske bank 3 t 2011
Danske bank 3 t 2011Danske bank 3 t 2011
Danske bank 3 t 2011Frank Ragol
 
Mining%20bill %20 impact%20analysis-eu-080711
Mining%20bill %20 impact%20analysis-eu-080711Mining%20bill %20 impact%20analysis-eu-080711
Mining%20bill %20 impact%20analysis-eu-080711Angel Broking
 
July 2016 Zynex Investor Presentation
July 2016 Zynex Investor PresentationJuly 2016 Zynex Investor Presentation
July 2016 Zynex Investor PresentationMartin Sandgaard
 
tenet healthcare Q206Earnings_5_
tenet healthcare  Q206Earnings_5_tenet healthcare  Q206Earnings_5_
tenet healthcare Q206Earnings_5_finance42
 

What's hot (20)

Hci 2012 2_q_con_eng_final_
Hci 2012 2_q_con_eng_final_Hci 2012 2_q_con_eng_final_
Hci 2012 2_q_con_eng_final_
 
MindTree: Prospect looks upbeat; buy
MindTree: Prospect looks upbeat; buyMindTree: Prospect looks upbeat; buy
MindTree: Prospect looks upbeat; buy
 
Apresentao3 t10 ing
Apresentao3 t10 ingApresentao3 t10 ing
Apresentao3 t10 ing
 
634926580024019075
634926580024019075634926580024019075
634926580024019075
 
Resultados2008
Resultados2008Resultados2008
Resultados2008
 
Expeditors International of Washington, 4th07qer
Expeditors International of Washington, 4th07qerExpeditors International of Washington, 4th07qer
Expeditors International of Washington, 4th07qer
 
2분기 영문 검토보고서
2분기 영문 검토보고서2분기 영문 검토보고서
2분기 영문 검토보고서
 
MindTree: Sharpened focus on growth, but rich valuation, accumulate - Prabhud...
MindTree: Sharpened focus on growth, but rich valuation, accumulate - Prabhud...MindTree: Sharpened focus on growth, but rich valuation, accumulate - Prabhud...
MindTree: Sharpened focus on growth, but rich valuation, accumulate - Prabhud...
 
카드 영문 수정본
카드 영문 수정본카드 영문 수정본
카드 영문 수정본
 
Ocbc nisp am t4-2011
Ocbc nisp am t4-2011Ocbc nisp am t4-2011
Ocbc nisp am t4-2011
 
2012 Supplementary Appropriation Law
2012 Supplementary Appropriation Law2012 Supplementary Appropriation Law
2012 Supplementary Appropriation Law
 
Credit Corp - turnaround in performance
Credit Corp - turnaround in performance Credit Corp - turnaround in performance
Credit Corp - turnaround in performance
 
Apresentação 3 t11 inglês
Apresentação 3 t11 inglêsApresentação 3 t11 inglês
Apresentação 3 t11 inglês
 
Expeditors International of Washington, 2nd07qer
Expeditors International of Washington, 2nd07qerExpeditors International of Washington, 2nd07qer
Expeditors International of Washington, 2nd07qer
 
Danske bank 3 t 2011
Danske bank 3 t 2011Danske bank 3 t 2011
Danske bank 3 t 2011
 
2011 q4
2011 q42011 q4
2011 q4
 
Mining%20bill %20 impact%20analysis-eu-080711
Mining%20bill %20 impact%20analysis-eu-080711Mining%20bill %20 impact%20analysis-eu-080711
Mining%20bill %20 impact%20analysis-eu-080711
 
July 2016 Zynex Investor Presentation
July 2016 Zynex Investor PresentationJuly 2016 Zynex Investor Presentation
July 2016 Zynex Investor Presentation
 
tenet healthcare Q206Earnings_5_
tenet healthcare  Q206Earnings_5_tenet healthcare  Q206Earnings_5_
tenet healthcare Q206Earnings_5_
 
Resultados bayer
Resultados bayerResultados bayer
Resultados bayer
 

Viewers also liked

Integrated strategic communication as a one-stop solution
Integrated strategic communication as a one-stop solutionIntegrated strategic communication as a one-stop solution
Integrated strategic communication as a one-stop solutionJP KOM GmbH
 
Csod investor deck first quarterv19
Csod investor deck first quarterv19Csod investor deck first quarterv19
Csod investor deck first quarterv19ircornerstone
 
Investor Presentation June 2016
Investor Presentation June 2016Investor Presentation June 2016
Investor Presentation June 2016Intact
 
Hard Assets Management Investor Presentation
Hard Assets Management Investor PresentationHard Assets Management Investor Presentation
Hard Assets Management Investor PresentationRedChip Companies, Inc.
 
Interpace Diagnostics Investor Presentation
Interpace Diagnostics Investor PresentationInterpace Diagnostics Investor Presentation
Interpace Diagnostics Investor PresentationRedChip Companies, Inc.
 
Pva barclays investor presentation (9 6 11)
Pva barclays investor presentation (9 6 11)Pva barclays investor presentation (9 6 11)
Pva barclays investor presentation (9 6 11)PennVirginiaCorp
 
Cardiff International, Inc. Investor Deck
Cardiff International, Inc. Investor DeckCardiff International, Inc. Investor Deck
Cardiff International, Inc. Investor DeckRedChip Companies, Inc.
 
Hard Asset Management Investor Presentation
Hard Asset Management Investor PresentationHard Asset Management Investor Presentation
Hard Asset Management Investor PresentationRedChip Companies, Inc.
 
Trupanion Investor Presentation
Trupanion Investor PresentationTrupanion Investor Presentation
Trupanion Investor Presentationtrupanion
 
Daniel Wilhelmi: Der Sentiment Trader
Daniel Wilhelmi: Der Sentiment TraderDaniel Wilhelmi: Der Sentiment Trader
Daniel Wilhelmi: Der Sentiment TraderInvestor Verlag
 
André Doerk: Der Silicon Valley Insider
André Doerk: Der Silicon Valley InsiderAndré Doerk: Der Silicon Valley Insider
André Doerk: Der Silicon Valley InsiderInvestor Verlag
 
Gerhard Massenbauer: Der Massenbauer Ansatz
Gerhard Massenbauer: Der Massenbauer AnsatzGerhard Massenbauer: Der Massenbauer Ansatz
Gerhard Massenbauer: Der Massenbauer AnsatzInvestor Verlag
 

Viewers also liked (20)

Integrated strategic communication as a one-stop solution
Integrated strategic communication as a one-stop solutionIntegrated strategic communication as a one-stop solution
Integrated strategic communication as a one-stop solution
 
Csod investor deck first quarterv19
Csod investor deck first quarterv19Csod investor deck first quarterv19
Csod investor deck first quarterv19
 
Investor Presentation June 2016
Investor Presentation June 2016Investor Presentation June 2016
Investor Presentation June 2016
 
Sofas power
Sofas powerSofas power
Sofas power
 
Knot Offshore Partners LP Investor Deck
Knot Offshore Partners LP Investor DeckKnot Offshore Partners LP Investor Deck
Knot Offshore Partners LP Investor Deck
 
Hard Assets Management Investor Presentation
Hard Assets Management Investor PresentationHard Assets Management Investor Presentation
Hard Assets Management Investor Presentation
 
GE International Investor Deck
GE International Investor DeckGE International Investor Deck
GE International Investor Deck
 
Interpace Diagnostics Investor Presentation
Interpace Diagnostics Investor PresentationInterpace Diagnostics Investor Presentation
Interpace Diagnostics Investor Presentation
 
CLPI Investor Presentation
CLPI Investor PresentationCLPI Investor Presentation
CLPI Investor Presentation
 
Pva barclays investor presentation (9 6 11)
Pva barclays investor presentation (9 6 11)Pva barclays investor presentation (9 6 11)
Pva barclays investor presentation (9 6 11)
 
Investor presentation November 2013
Investor presentation November 2013Investor presentation November 2013
Investor presentation November 2013
 
Money On Mobile
Money On MobileMoney On Mobile
Money On Mobile
 
Cardiff International, Inc. Investor Deck
Cardiff International, Inc. Investor DeckCardiff International, Inc. Investor Deck
Cardiff International, Inc. Investor Deck
 
Hard Asset Management Investor Presentation
Hard Asset Management Investor PresentationHard Asset Management Investor Presentation
Hard Asset Management Investor Presentation
 
Trupanion Investor Presentation
Trupanion Investor PresentationTrupanion Investor Presentation
Trupanion Investor Presentation
 
Cogint management investor presentation
Cogint management investor presentationCogint management investor presentation
Cogint management investor presentation
 
Daniel Wilhelmi: Der Sentiment Trader
Daniel Wilhelmi: Der Sentiment TraderDaniel Wilhelmi: Der Sentiment Trader
Daniel Wilhelmi: Der Sentiment Trader
 
André Doerk: Der Silicon Valley Insider
André Doerk: Der Silicon Valley InsiderAndré Doerk: Der Silicon Valley Insider
André Doerk: Der Silicon Valley Insider
 
Gerhard Massenbauer: Der Massenbauer Ansatz
Gerhard Massenbauer: Der Massenbauer AnsatzGerhard Massenbauer: Der Massenbauer Ansatz
Gerhard Massenbauer: Der Massenbauer Ansatz
 
Joey New York Investor Deck
Joey New York Investor DeckJoey New York Investor Deck
Joey New York Investor Deck
 

Similar to Apr 2014 investor presentation

Zynex December 2013 Investor Presentation
Zynex December 2013 Investor PresentationZynex December 2013 Investor Presentation
Zynex December 2013 Investor Presentationissuerdirect
 
Immunotec Press Release Q4 2008
Immunotec  Press Release  Q4 2008Immunotec  Press Release  Q4 2008
Immunotec Press Release Q4 2008Avis Betancourt
 
Balance SheetGREAT BASIN SCIENTIFIC, INC.September 30, 2015Decembe.docx
Balance SheetGREAT BASIN SCIENTIFIC, INC.September 30, 2015Decembe.docxBalance SheetGREAT BASIN SCIENTIFIC, INC.September 30, 2015Decembe.docx
Balance SheetGREAT BASIN SCIENTIFIC, INC.September 30, 2015Decembe.docxrock73
 
Muthengi mike bamburi financial model - enhancement
Muthengi mike   bamburi financial model - enhancementMuthengi mike   bamburi financial model - enhancement
Muthengi mike bamburi financial model - enhancementMike Muthengi
 
1Exercise 8-4The ledger of Wainwright Company at the end of the cu.docx
1Exercise 8-4The ledger of Wainwright Company at the end of the cu.docx1Exercise 8-4The ledger of Wainwright Company at the end of the cu.docx
1Exercise 8-4The ledger of Wainwright Company at the end of the cu.docxvickeryr87
 
Statistical Analysis FY 2013 FY 2014 FY 2015 .docx
Statistical Analysis  FY 2013 FY 2014 FY 2015 .docxStatistical Analysis  FY 2013 FY 2014 FY 2015 .docx
Statistical Analysis FY 2013 FY 2014 FY 2015 .docxwhitneyleman54422
 
December 2015 ZYXI Investor Presentation
December 2015 ZYXI Investor PresentationDecember 2015 ZYXI Investor Presentation
December 2015 ZYXI Investor PresentationPritesh Patel
 
danaher 06_4Q_Release
danaher 06_4Q_Releasedanaher 06_4Q_Release
danaher 06_4Q_Releasefinance24
 
nationwide 2Q07 Statistical Supplement
nationwide 2Q07 Statistical Supplementnationwide 2Q07 Statistical Supplement
nationwide 2Q07 Statistical Supplementfinance11
 
Consolidated Statements of OperConsolidated Statements of Operatio.docx
Consolidated Statements of OperConsolidated Statements of Operatio.docxConsolidated Statements of OperConsolidated Statements of Operatio.docx
Consolidated Statements of OperConsolidated Statements of Operatio.docxdonnajames55
 
OVERLAKE HOSPITAL MEDICAL CENTER Consolidated Financ.docx
OVERLAKE HOSPITAL MEDICAL CENTER Consolidated Financ.docxOVERLAKE HOSPITAL MEDICAL CENTER Consolidated Financ.docx
OVERLAKE HOSPITAL MEDICAL CENTER Consolidated Financ.docxalfred4lewis58146
 
BTE 302TEST 1NameCMR 302Test IAnswer the Following.docx
BTE 302TEST 1NameCMR 302Test IAnswer the Following.docxBTE 302TEST 1NameCMR 302Test IAnswer the Following.docx
BTE 302TEST 1NameCMR 302Test IAnswer the Following.docxcurwenmichaela
 
regions 1Q 08 SUPP
regions 1Q 08 SUPPregions 1Q 08 SUPP
regions 1Q 08 SUPPfinance25
 
regions 1Q 08 SUPP
regions 1Q 08 SUPPregions 1Q 08 SUPP
regions 1Q 08 SUPPfinance25
 
regions 1Q 08 SUPP
regions 1Q 08 SUPPregions 1Q 08 SUPP
regions 1Q 08 SUPPfinance25
 
regions 1Q 08 SUPP
regions 1Q 08 SUPPregions 1Q 08 SUPP
regions 1Q 08 SUPPfinance25
 
coventry health care annual reports2003
coventry health care annual reports2003 coventry health care annual reports2003
coventry health care annual reports2003 finance27
 
Wassim Zhani Kroger Value.pdf
Wassim Zhani Kroger Value.pdfWassim Zhani Kroger Value.pdf
Wassim Zhani Kroger Value.pdfWassim Zhani
 

Similar to Apr 2014 investor presentation (20)

Zyxi ppt (july 2012)
Zyxi ppt (july 2012)Zyxi ppt (july 2012)
Zyxi ppt (july 2012)
 
Zynex December 2013 Investor Presentation
Zynex December 2013 Investor PresentationZynex December 2013 Investor Presentation
Zynex December 2013 Investor Presentation
 
Immunotec Press Release Q4 2008
Immunotec  Press Release  Q4 2008Immunotec  Press Release  Q4 2008
Immunotec Press Release Q4 2008
 
Balance SheetGREAT BASIN SCIENTIFIC, INC.September 30, 2015Decembe.docx
Balance SheetGREAT BASIN SCIENTIFIC, INC.September 30, 2015Decembe.docxBalance SheetGREAT BASIN SCIENTIFIC, INC.September 30, 2015Decembe.docx
Balance SheetGREAT BASIN SCIENTIFIC, INC.September 30, 2015Decembe.docx
 
Muthengi mike bamburi financial model - enhancement
Muthengi mike   bamburi financial model - enhancementMuthengi mike   bamburi financial model - enhancement
Muthengi mike bamburi financial model - enhancement
 
1Exercise 8-4The ledger of Wainwright Company at the end of the cu.docx
1Exercise 8-4The ledger of Wainwright Company at the end of the cu.docx1Exercise 8-4The ledger of Wainwright Company at the end of the cu.docx
1Exercise 8-4The ledger of Wainwright Company at the end of the cu.docx
 
Statistical Analysis FY 2013 FY 2014 FY 2015 .docx
Statistical Analysis  FY 2013 FY 2014 FY 2015 .docxStatistical Analysis  FY 2013 FY 2014 FY 2015 .docx
Statistical Analysis FY 2013 FY 2014 FY 2015 .docx
 
December 2015 ZYXI Investor Presentation
December 2015 ZYXI Investor PresentationDecember 2015 ZYXI Investor Presentation
December 2015 ZYXI Investor Presentation
 
danaher 06_4Q_Release
danaher 06_4Q_Releasedanaher 06_4Q_Release
danaher 06_4Q_Release
 
OXYS Investor Presentation
OXYS Investor PresentationOXYS Investor Presentation
OXYS Investor Presentation
 
nationwide 2Q07 Statistical Supplement
nationwide 2Q07 Statistical Supplementnationwide 2Q07 Statistical Supplement
nationwide 2Q07 Statistical Supplement
 
Consolidated Statements of OperConsolidated Statements of Operatio.docx
Consolidated Statements of OperConsolidated Statements of Operatio.docxConsolidated Statements of OperConsolidated Statements of Operatio.docx
Consolidated Statements of OperConsolidated Statements of Operatio.docx
 
OVERLAKE HOSPITAL MEDICAL CENTER Consolidated Financ.docx
OVERLAKE HOSPITAL MEDICAL CENTER Consolidated Financ.docxOVERLAKE HOSPITAL MEDICAL CENTER Consolidated Financ.docx
OVERLAKE HOSPITAL MEDICAL CENTER Consolidated Financ.docx
 
BTE 302TEST 1NameCMR 302Test IAnswer the Following.docx
BTE 302TEST 1NameCMR 302Test IAnswer the Following.docxBTE 302TEST 1NameCMR 302Test IAnswer the Following.docx
BTE 302TEST 1NameCMR 302Test IAnswer the Following.docx
 
regions 1Q 08 SUPP
regions 1Q 08 SUPPregions 1Q 08 SUPP
regions 1Q 08 SUPP
 
regions 1Q 08 SUPP
regions 1Q 08 SUPPregions 1Q 08 SUPP
regions 1Q 08 SUPP
 
regions 1Q 08 SUPP
regions 1Q 08 SUPPregions 1Q 08 SUPP
regions 1Q 08 SUPP
 
regions 1Q 08 SUPP
regions 1Q 08 SUPPregions 1Q 08 SUPP
regions 1Q 08 SUPP
 
coventry health care annual reports2003
coventry health care annual reports2003 coventry health care annual reports2003
coventry health care annual reports2003
 
Wassim Zhani Kroger Value.pdf
Wassim Zhani Kroger Value.pdfWassim Zhani Kroger Value.pdf
Wassim Zhani Kroger Value.pdf
 

More from Company Spotlight

Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 YearsPresentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 YearsCompany Spotlight
 
Cypress Development Corp. Investor Presentation
Cypress Development Corp. Investor PresentationCypress Development Corp. Investor Presentation
Cypress Development Corp. Investor PresentationCompany Spotlight
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationCompany Spotlight
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCompany Spotlight
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. PresentationCompany Spotlight
 
Aben Resources Ltd. Presentation
Aben Resources Ltd. PresentationAben Resources Ltd. Presentation
Aben Resources Ltd. PresentationCompany Spotlight
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationCompany Spotlight
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. PresentationCompany Spotlight
 
Aben Resources Ltd. Presentation
Aben Resources Ltd. PresentationAben Resources Ltd. Presentation
Aben Resources Ltd. PresentationCompany Spotlight
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCompany Spotlight
 
TerraX Minerals - Corporate Presentation
TerraX Minerals - Corporate PresentationTerraX Minerals - Corporate Presentation
TerraX Minerals - Corporate PresentationCompany Spotlight
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationCompany Spotlight
 
TerraX Minerals, Inc. Corporate Presentation
TerraX Minerals, Inc. Corporate PresentationTerraX Minerals, Inc. Corporate Presentation
TerraX Minerals, Inc. Corporate PresentationCompany Spotlight
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. PresentationCompany Spotlight
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCompany Spotlight
 

More from Company Spotlight (20)

Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 YearsPresentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
 
Aben resources presentation
Aben resources presentationAben resources presentation
Aben resources presentation
 
Aben Resources Ltd.
Aben Resources Ltd.Aben Resources Ltd.
Aben Resources Ltd.
 
Cypress Development Corp. Investor Presentation
Cypress Development Corp. Investor PresentationCypress Development Corp. Investor Presentation
Cypress Development Corp. Investor Presentation
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate Presentation
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate Presentation
 
Aben Resources Ltd.
Aben Resources Ltd.Aben Resources Ltd.
Aben Resources Ltd.
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. Presentation
 
Aben Resources Ltd. Presentation
Aben Resources Ltd. PresentationAben Resources Ltd. Presentation
Aben Resources Ltd. Presentation
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate Presentation
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. Presentation
 
Aben Resources Ltd. Presentation
Aben Resources Ltd. PresentationAben Resources Ltd. Presentation
Aben Resources Ltd. Presentation
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate Presentation
 
TerraX Minerals - Corporate Presentation
TerraX Minerals - Corporate PresentationTerraX Minerals - Corporate Presentation
TerraX Minerals - Corporate Presentation
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate Presentation
 
Cypress Development Corp
Cypress Development CorpCypress Development Corp
Cypress Development Corp
 
TerraX Minerals, Inc. Corporate Presentation
TerraX Minerals, Inc. Corporate PresentationTerraX Minerals, Inc. Corporate Presentation
TerraX Minerals, Inc. Corporate Presentation
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. Presentation
 
Cypress Development Corp
Cypress Development CorpCypress Development Corp
Cypress Development Corp
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate Presentation
 

Recently uploaded

abortion pills in Riyadh+966572737505 Cytotec Riyadh
abortion pills in  Riyadh+966572737505    Cytotec Riyadhabortion pills in  Riyadh+966572737505    Cytotec Riyadh
abortion pills in Riyadh+966572737505 Cytotec Riyadhsamsungultra782445
 
Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024TeckResourcesLtd
 
Teck Supplemental Information, May 2, 2024
Teck Supplemental Information, May 2, 2024Teck Supplemental Information, May 2, 2024
Teck Supplemental Information, May 2, 2024TeckResourcesLtd
 
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样dyuozua
 
一比一原版(RUG毕业证书)格罗宁根大学毕业证成绩单原件一模一样
一比一原版(RUG毕业证书)格罗宁根大学毕业证成绩单原件一模一样一比一原版(RUG毕业证书)格罗宁根大学毕业证成绩单原件一模一样
一比一原版(RUG毕业证书)格罗宁根大学毕业证成绩单原件一模一样dyuozua
 
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样dyuozua
 
Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024CollectiveMining1
 
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCamil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCAMILRI
 
一比一原版(Mac毕业证书)麦克马斯特大学毕业证成绩单原件一模一样
一比一原版(Mac毕业证书)麦克马斯特大学毕业证成绩单原件一模一样一比一原版(Mac毕业证书)麦克马斯特大学毕业证成绩单原件一模一样
一比一原版(Mac毕业证书)麦克马斯特大学毕业证成绩单原件一模一样dyuozua
 
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样dyuozua
 
一比一原版(UCD毕业证书)都柏林大学毕业证成绩单原件一模一样
一比一原版(UCD毕业证书)都柏林大学毕业证成绩单原件一模一样一比一原版(UCD毕业证书)都柏林大学毕业证成绩单原件一模一样
一比一原版(UCD毕业证书)都柏林大学毕业证成绩单原件一模一样dyuozua
 
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024Osisko Gold Royalties Ltd
 
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样dyuozua
 
Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024CollectiveMining1
 
原件一样(USC毕业证)南加州大学毕业证成绩单留信学历认证可查
原件一样(USC毕业证)南加州大学毕业证成绩单留信学历认证可查原件一样(USC毕业证)南加州大学毕业证成绩单留信学历认证可查
原件一样(USC毕业证)南加州大学毕业证成绩单留信学历认证可查lezegu21r
 
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCamil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCAMILRI
 
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样dyuozua
 
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样dyuozua
 
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样dyuozua
 
皇后大学毕业证
皇后大学毕业证皇后大学毕业证
皇后大学毕业证dyuozua
 

Recently uploaded (20)

abortion pills in Riyadh+966572737505 Cytotec Riyadh
abortion pills in  Riyadh+966572737505    Cytotec Riyadhabortion pills in  Riyadh+966572737505    Cytotec Riyadh
abortion pills in Riyadh+966572737505 Cytotec Riyadh
 
Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024
 
Teck Supplemental Information, May 2, 2024
Teck Supplemental Information, May 2, 2024Teck Supplemental Information, May 2, 2024
Teck Supplemental Information, May 2, 2024
 
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
 
一比一原版(RUG毕业证书)格罗宁根大学毕业证成绩单原件一模一样
一比一原版(RUG毕业证书)格罗宁根大学毕业证成绩单原件一模一样一比一原版(RUG毕业证书)格罗宁根大学毕业证成绩单原件一模一样
一比一原版(RUG毕业证书)格罗宁根大学毕业证成绩单原件一模一样
 
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
 
Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024
 
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCamil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdf
 
一比一原版(Mac毕业证书)麦克马斯特大学毕业证成绩单原件一模一样
一比一原版(Mac毕业证书)麦克马斯特大学毕业证成绩单原件一模一样一比一原版(Mac毕业证书)麦克马斯特大学毕业证成绩单原件一模一样
一比一原版(Mac毕业证书)麦克马斯特大学毕业证成绩单原件一模一样
 
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
 
一比一原版(UCD毕业证书)都柏林大学毕业证成绩单原件一模一样
一比一原版(UCD毕业证书)都柏林大学毕业证成绩单原件一模一样一比一原版(UCD毕业证书)都柏林大学毕业证成绩单原件一模一样
一比一原版(UCD毕业证书)都柏林大学毕业证成绩单原件一模一样
 
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
 
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
 
Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024
 
原件一样(USC毕业证)南加州大学毕业证成绩单留信学历认证可查
原件一样(USC毕业证)南加州大学毕业证成绩单留信学历认证可查原件一样(USC毕业证)南加州大学毕业证成绩单留信学历认证可查
原件一样(USC毕业证)南加州大学毕业证成绩单留信学历认证可查
 
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCamil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdf
 
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
 
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
 
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
 
皇后大学毕业证
皇后大学毕业证皇后大学毕业证
皇后大学毕业证
 

Apr 2014 investor presentation

  • 1.
  • 2. Forward Looking Statements Statements made in this presentation include financial estimates and forward-looking statements that are not historical facts. Each of these estimates and forward-looking statements involves risk and uncertainties. These estimates are based on present circumstances, information currently available, and assumptions about future revenues, industry growth, and general economic conditions. Estimates are inherently uncertain as they are based on assumptions concerning future events. No representations can be made as to the accuracy of such information or the reliability of such assumptions. Accordingly, actual revenues and expenditures may vary significantly from the Company’s estimates, and actual results or developments may differ materially from those expressed or implied by the forward-looking statements. Factors that could cause actual results to differ from the financial estimates and forward-looking statements in this presentation include those described in the Company’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as updated in 2014 quarter periods. Therefore, neither the Company’s estimates nor the assumptions upon which they are based are to be interpreted as a guarantee or promise of the Company or management. The Company has no obligation to modify, amend, update, alter, or change the estimates contained herein. Investor Relations Zynex, Inc. 9990 Park Meadows Drive Lone Tree, CO 80124 Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynex.com Apr 2014 2OTCQB: ZYXI
  • 3. Zynex Overview •  Medical Device Manufacturer & Compound Pharmacy o  Non-invasive, conservative pain treatment o  Neuro-Monitoring o  Blood volume monitoring o  Physician and hospital billing o  International sales •  Publicly Traded OTCQB: ZYXI •  In operation since 1996, headquartered in Lone Tree, Colorado •  >40%+ recurring revenue with more than 250,000 patients treated since inception •  High GPM of >70% •  Estimated $5b market potential Apr 2014 3OTCQB: ZYXI
  • 4. Business Structure Zynex, Inc. Medical Inc. Electrotherapy PharmaZy (Compound Pharmacy) Neurodiagnostics Inc. EEG (Brain Diagnostic) Sleep (lab/home) (Diagnostic/ Treatment Monitoring Solutions Blood Volume Monitor (R&D) Billing and consulting Private Practice Billing International Apr 2014 4OTCQB: ZYXI
  • 5. Business Unit Summary •  ZYNEX MEDICAL (ZMI) o  Non-invasive electrotherapy pain management devices “TENS” (97% of historical revenue) •  RX required, insurance billed •  >70% GP, >40% recurring revenue (consumable supplies) o  Topical/transdermal pain cream (introduced Dec 2013) •  RX required, insurance billed, complimentary to TENS with same sales force •  >80% GP and recurring monthly refill prescriptions •  ZYNEX NEURODIAGNOSTICS (ZND) o  EEG EMG diagnostics B:B products (2% of historical revenue) •  ZYNEX MONITORING SOLUTIONS (ZMS) o  In development, non-invasive blood volume monitor (Zero revenue, in development) •  ZYNEX BILLING AND CONSULTING (ZBC) o  Outsourced billing for physicians and hospitals (1% of historical revenue) •  ZYNEX INTERNATIONAL (ZINT) o  International sales for all Zynex products (1% of historical revenue-all divisions) Apr 2014 5OTCQB: ZYXI
  • 6. Products – Zynex Medical •  Complete line of electrotherapy pain management devices-FDA cleared and CE marked •  Augments healing, alleviates swelling through increased blood circulation, and reduces both acute/chronic pain through the use of electrical currents •  Consumables required •  Require a prescription •  Reimbursed by health insurance •  May be rented or purchased Apr 2014 6 NexWave TruWave+ E-Wave IF8000 IF8100 Iontophoresis Consumables (battery/electrode) OTCQB: ZYXI
  • 7. Products – Zynex Medical •  Stroke/spinal cord rehabilitation devices-FDA cleared and CE marked •  Augment healing, as well as assist in recovery for stroke, Spinal Cord Injuries and Traumatic Brain Injury, retrains muscles, increases range of motion •  Consumables required Apr 2014 7 NeuroMove Consumables (electrodes) OTCQB: ZYXI
  • 8. Products – Monitoring Solutions •  In development – non invasive blood volume monitor •  Used in operating and recovery rooms to detect blood loss and internal bleeding •  Clinical trials commenced •  Patent filed Apr 2014 8 Blood Volume Monitor (in development) OTCQB: ZYXI
  • 10. Financial Summary Apr 2014 10OTCQB: ZYXI Annual Financial Data (000’s) except per share 2013 2012 2011 2010 2009 2008 2007 Net Revenue $21,684 $39,666 $34,148 $24,085 $18,681 $11,764 $8,048 Gross Profit 13,544 30,896 26,777 18,883 14,888 9,524 7,319 Net Income (loss) (7,301) 1,553 1,564 350 2,382 111 2,131 Cash 323 823 789 602 863 -- -- EPS (0.23) 0.05 0.05 0.01 0.08 0.00 0.07 Cash Flow from Operations (382) (879) (362) (665) 3,648 (715) 746 Total Stockholders’ Equity 4,848 12,055 10,140 8,182 7,486 4,774 3,618 Common Shares Outstanding 31,171 31,148 30,800 30,600 30,500 29,900 26,800  
  • 11. Balance Sheet Apr 2014 11OTCQB: ZYXI Dec-­‐13 Dec-­‐12 Dec-­‐11 Cash 323                                   823                                   789                                   A/R 7,033                             12,224                       10,984                       Inventory 5,002                             6,160                             4,557                             Other  Assets 1,346                             2,155                             1,718                                  Current  Assets 13,704                       21,362                       18,048                       PP&E 2,891                             3,851                             3,422                             Other  Assets 626                                   723                                   315                                        Total  Assets 17,221$                   25,936$                   21,785$                   Line  of  Credit 5,820                             5,906                             3,290                             Other  Liabilities 3,864                             6,187                             6,460                                  Current  Liabilities 9,684                             12,093                       9,750                             Other  Liabilities 2,689                             1,788                             1,896                                  Total  Liabilities 12,373                       13,881                       11,646                       Common  Stock 31                                       31                                       31                                       Paid-­‐in-­‐capital 5,586                             5,453                             5,095                             Retained  Earnings (735)                                 6,566                             5,013                             Noncontrolling  interest (34)                                     5                                           -­‐                                          Total  Stockholders'  Equity 4,848                             12,055                       10,139                            Total  Liab.  And  S.Equity 17,221$                   25,936$                   21,785$                  
  • 12. Available Market Apr 2014 12OTCQB: ZYXI PAST AVAILABLE MARKET ~$4B CURRENT AVAILABLE MARKET ~$5B ZYNEX MEDICAL ZYNEX MEDICAL Electrotherapy Devices $550M Electrotherapy Devices $275M Compound Pain Cream $1.8B ZYNEX MONITORING SOLUTIONS ZYNEX MONITORING SOLUTIONS Cardiac Monitoring Devices $3B Cardiac Monitoring Devices $3B ZYNEX NEURODIAGNOSTICS ZYNEX NEURODIAGNOSTICS Biofeedback/Rehab $220M Biofeedback/Rehab $220M Market size based on internal management estimates and various market sources
  • 13. Business Factors •  Zynex Medical – TENS o  TENS business slowed down in 2013 •  Healthcare reform o  TENS business beginning to grow again early 2014 •  Zynex Medical – Compound Pharmacy o  Compound pharmacy growth will have impact on second half 2014 financial results Apr 2014 13OTCQB: ZYXI
  • 14. Zynex – Looking Forward •  Zynex Medical (ZMI) o  Pain Cream/Compound Pharmacy facts •  Complements Zynex TENS non-invasive pain management product and is sold through same TENS channel and customer •  Highly fragmented with low concentration •  GM 80%+ •  Zynex is licensed by DEA and 32 states (moving to be licensed in all states during 2014) Apr 2014 14OTCQB: ZYXI
  • 15. Zynex – Looking Forward •  Zynex Monitoring Solutions: o  Blood Volume Monitor at commercialization •  Early warning that patient condition is likely to deteriorate •  Utilizes multiple physiological •  Enables a higher level of care than traditional vital sign monitoring •  Effective in multiple care environments (e.g. operating room, recovery and trauma) •  Zynex Billing and Consulting(ZBC) o  Insurance billing and consulting for physicians and hospitals o  Looking to assume/acquire additional billing companies o  Provides recurring service based revenue, while leveraging insurance billing core competency Apr 2014 15OTCQB: ZYXI
  • 16. Future Objectives •  Listing on AMEX/NASDAQ •  Develop devices and applications with high GPM •  Continue to grow recurring revenue •  Take only calculated risks •  Generate net earnings and positive free cash flow •  Long term - utilize a mix of acquisitions and organic based growth to drive valuation=stock price=private equity with low dilution and/or loan-based financing Apr 2014 16OTCQB: ZYXI
  • 17. History 1996 •  Founded by Thomas Sandgaard 1999 •  FDA clearance on first Zynex device 2001 •  Shifted from wholesale to direct sales to physicians and patients 2004 •  Reverse merger into a public shell 2008 •  Received European CE mark on key products 2010 •  Established NeuroDiagnostics (EEG/Sleep) and Monitoring (blood volume) subsidiaries 2011 •  Commenced clinical evaluations for Blood Volume Monitor device 2013 •  Impacted by Health Care Reform – restructured core business, expanded product offers to in-house compounded pain cream 2014 •  Launched compound pharmacy (DEA + 32 state licenses obtained) Apr 2014 17OTCQB: ZYXI
  • 18. Corporate & Ownership Structure Apr 2014 18 Common Stock: 31,000,000 shares outstanding OTCBB: ZYXI Auditors: GHP Horwath Counsel: Perkins Coie OTCQB: ZYXI
  • 19. Management Team Bio Thomas Sandgaard has been the Chairman of the Board, President and Chief Executive Officer of Zynex, Inc. since founding the company in 1996. He has previously held management positions with companies such as ITT, Siemens, GN Danavox, Dataco and Philips. Most of his work has been in the areas of international sales and distribution, technology transfers, mergers and marketing management in the semiconductor, telecommunications, data communications and medical equipment industries. Mr. Sandgaard has a degree in electronics engineering from Denmark’s Odense University of Engineering and an MBA from Copenhagen Business School. Mr. Sandgaard has an in-depth knowledge of the industry and is the driving force as to the Company strategies. Anthony Scalese has been Chief Financial Officer of Zynex, Inc. since September 2010. Mr. Scalese has over 15 years of experience in accounting, finance and operations and has spent the past 13 years of his career in the high-tech and healthcare industries. His most recent position was Chief Financial Officer for Qualmark Corporation, in which he also served as President for various subsidiaries of Qualmark. He previously held positions at Coram Healthcare (now Apria Healthcare) as well as Foundation Health Systems (now Healthnet). Mr. Scalese is a Certified Public Accountant licensed in Colorado, received a Masters in Business Administration from the University of Colorado and a Bachelor of Science in Business Administration-Accounting from Colorado State University. Apr 2014 19OTCQB: ZYXI
  • 21. Contact Information For more information, please contact: Investor Relations Zynex, Inc. 9990 Park Meadows Drive Lone Tree, CO 80124 Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynex.com Apr 2014 21OTCQB: ZYXI
  • 22. Stock Symbol ZYXI   Apr 2014 22OTCQB: ZYXI